Ubiquitous yet unique, lipid droplets are intracellular organelles that are increasingly being
recognized for their versatility beyond energy storage. Advances uncovering the intricacies …

Nonalcoholic fatty liver disease (NAFLD) and its more severe form, nonalcoholic
steatohepatitis (NASH), represent a growing worldwide epidemic and a high unmet medical …

Alcohol-associated liver disease (ALD) is a major cause of chronic liver disease worldwide,
and comprises a spectrum of several different disorders, including simple steatosis …

Nonalcoholic fatty liver disease (NAFLD), including its more severe manifestation,
nonalcoholic steatohepatitis (NASH), has a global prevalence of 20–25% and is a major …

The metabolic state represents a major hurdle for an effective adoptive T cell therapy (ACT).
Indeed, specific lipids can harm CD8+ T cell (CTL) mitochondrial integrity, leading to …

Nonalcoholic fatty liver disease (NAFLD) is common and partially heritable and has no
effective treatments. We carried out a genome-wide association study (GWAS) meta …

Nonalcoholic fatty liver disease (NAFLD) is the leading chronic liver disease worldwide. Its
more advanced subtype, nonalcoholic steatohepatitis (NASH), connotes progressive liver …

Nonalcoholic fatty liver disease (NAFLD) is one of the most common liver diseases
worldwide and is often associated with aspects of metabolic syndrome. Despite its …

Nonalcoholic fatty liver disease (NAFLD) has become a serious public health issue not only
in Western countries but also in Japan. Within the wide spectrum of NAFLD, nonalcoholic …

Fatty liver disease (FLD) caused by metabolic dysfunction is the leading cause of liver
disease and the prevalence is rising, especially in women. Although during reproductive …